CONTEXT: A company looking to explore new ways to expand the use of RWD in drug development. By utilising the power of RWD to look at treatment models overall, it Continue Reading
CONTEXT: Commercial announcement of an updated RWE platform for collection of prospective study data along with external data sources from another leading RWE company (It must be getting crowded up Continue Reading
CONTEXT: Commercial announcement of another player in the RWE dataset market | The competition for people’s data is hotting up and you can get a sense for how valuable the Continue Reading
CONTEXT: An opinion piece on the value of data sets in biomedical and neuroimaging studies, but only where they are compatible | When we still don’t have a common charger for Continue Reading
CONTEXT: A claim that will no doubt be tested – “Regulatory-grade evidence”. What exactly constitutes regulatory-grade RWE? Time will tell as we move into a new era for RWR | Continue Reading
CONTEXT: Commercial announcement mirroring the developing trend in pulling together RWE data sources and analytical capabilities in response to the regulatory need for more granularity to assess the safety, health, Continue Reading
CONTEXT: Mostly advert for cox platform, but interesting EMR based use of RWD – stretching the definition of a decentralised study though, US Only IMPACT: RWE insights based on de-identified Continue Reading
Comments – Part of the growing trend for big pharma to secure bid data sources for their own use. A move in the right direction towards ‘regulatory grade’ RWE. READ Continue Reading
COMMENTS: Part of the growing trend for big pharma to secure bid data sources for their own use. IMPACT: A move in the right direction towards ‘regulatory grade’ RWE, READ Continue Reading
EXPERT NOTES: CONTEXT: EU, Commercial RWD Data Source IMPACT: Access to EU RWD, drive cutting edge improvements in patient outcome Time Taken = 3 mins QUOTES FROM SOURCE: 1. “NEW Continue Reading
